Michael Porter, Ph.D., has joined the board of directors of ExThera Medical Corporation, a privately held medical technology company focused on the therapeutic reduction of drug-resistant pathogens and sepsis mediators in whole blood. ExThera’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) has a CE Mark in Europe for the treatment of a wide range of bloodstream infections. In the USA Seraph 100 has Emergency Use Authorization from FDA, where it is being used successfully in the treatment of COVID-19 patients, many of whom are critically ill.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005367/en/
Michael Porter (Photo: Business Wire)
Professor Porter, the Bishop William Lawrence University Professor at Harvard Business School, is recognized as a leading authority on competitive strategy, the competitiveness and economic development of nations and regions, and the application of competition and strategy principles to address social problems such as health